GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019
September 24 2019 - 12:38PM
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich
Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the
world leader in the development and commercialization of
cannabinoid prescription medicines, today announced that Scott
Giacobello, GW’s Chief Financial Officer and Stephen Schultz, GW’s
Vice President of Investor Relations will present at the 2019
Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019
at 4:10 p.m. ET in New York, NY.
A live audio webcast of the presentation will be
available through GW’s corporate website at www.gwpharm.com on the
Investors section under Events & Presentations. A replay will
be available soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW’s lead
product, EPIDIOLEX (cannabidiol oral solution) is commercialized in
the US by its U.S. subsidiary Greenwich Biosciences for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older. This
product has received approval in Europe under the tradename
EPIDYOLEX. The Company continues to evaluate EPIDIOLEX in
additional rare conditions including Tuberous Sclerosis Complex
(TSC) and Rett syndrome. GW commercialized the world’s first
plant-derived cannabinoid prescription drug, Sativex® (nabiximols),
which is approved for the treatment of spasticity due to multiple
sclerosis in numerous countries outside the United States and for
which the Company is now advancing a late stage program in order to
seek FDA approval. The Company has a deep pipeline of additional
cannabinoid product candidates which includes compounds in Phase 1
and 2 trials for epilepsy, autism, glioblastoma, and schizophrenia.
For further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024